Key features and details
- Mouse monoclonal [ICRF44] to CD11b (FITC)
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Product nameAnti-CD11b antibody [ICRF44] (FITC)
See all CD11b primary antibodies
DescriptionMouse monoclonal [ICRF44] to CD11b (FITC)
ConjugationFITC. Ex: 493nm, Em: 528nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human CD11b. Rheumatoid synovial cells and Human monocytes.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.20
Preservative: 0.1% Sodium azide
Constituents: 0.16% Sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Concentration information loading...
- Anti-CD11b antibody [ICRF44], prediluted (PE/Cy7®) (ab135929)
- Anti-CD11b antibody [ICRF44], prediluted (Alexa Fluor® 488) (ab187597)
- Anti-CD11b antibody [ICRF44] (APC/Cy7®) (ab197129)
- Anti-CD11b antibody [ICRF44] (APC) (ab218639)
- Anti-CD11b antibody [ICRF44] (Biotin) (ab239235)
- Anti-CD11b antibody [ICRF44] (ab34216)
Our Abpromise guarantee covers the use of ab176541 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.|
FunctionIntegrin alpha-M/beta-2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin alpha-M/beta-2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain.
Tissue specificityPredominantly expressed in monocytes and granulocytes.
Involvement in diseaseGenetic variations in ITGAM has been associated with susceptibility to systemic lupus erythematosus type 6 (SLEB6) [MIM:609939]. Systemic lupus erythematosus (SLE) is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Sequence similaritiesBelongs to the integrin alpha chain family.
Contains 7 FG-GAP repeats.
Contains 1 VWFA domain.
DomainThe integrin I-domain (insert) is a VWFA domain. Integrins with I-domains do not undergo protease cleavage.
- Information by UniProt
- antigen CD11b (p170) antibody
- Antigen CD11b p170 antibody
- CD11 antigen like family member B antibody
ab176541 has not yet been referenced specifically in any publications.